Oncology Archives - Page 3 of 19

Targeting FAK Improves the Tumor Uptake of ADCs

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...

BRCA2 Deficient DLD-1 Model

BRCA1 and BRCA2 proteins are key components of the homologous recombination repair pathway for repairing double-stranded DNA breaks. Mutations in...

OncoWuXi Express: Evaluation of T Cell Engagers

Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as...

Small Molecule Reactivator of p53 Y220C Mutant

Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...

BaF3 Models Carrying HER2 Mutations

Frequently observed in NSCLC patients, the 4 amino acid YVMA insertion is the most common type of HER2 exon 20...

PRMT5 Related Tumor Models

Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. MTAP deletions occur in...

Developing Novel AR Mutant Prostate Cancer Models

Since prostate cancer heavily depends on androgen hormones for growth, targeting the androgen receptor (AR) signaling pathway is a key...

OncoWuXi Express: Anti-Tumor mRNA Drugs

OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well...

How Peptide Vaccines are Reshaping Cancer Immunotherapy

Research on cancer immunotherapy has firmly established immune cells as key players in effective cancer treatment. Peptide vaccines directly targeting...

Knowledge Library